Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 4:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,434 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: taxol Clear all
Not listed Phase 1 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer

NCT00004097
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
fluorouracil, gemcitabine hydrochloride, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 11, 2026, 4:57 PM EDT
Not listed Phase 2 Interventional

High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer

NCT00003284
View directory record Official record
Conditions
Lung Cancer
Interventions
filgrastim, carboplatin, etoposide, ifosfamide, paclitaxel, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer

NCT02210559
View directory record Official record
Conditions
Pancreatic Cancer (Unresectable)
Interventions
FG-3019, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Phase 2 Interventional Results available

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT00828009
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, Tecemotide, carboplatin, cyclophosphamide, paclitaxel, radiotherapy
Biological · Drug · Radiation
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
88
States / cities
Palo Alto, California • Stanford, California • Macon, Georgia + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors

NCT01188499
View directory record Official record
Conditions
Cancer
Interventions
Birinapant
Drug
Lead sponsor
TetraLogic Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Fort Lauderdale, Florida • Detroit, Michigan • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2016 · Synced Sep 11, 2026, 4:57 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

NCT07049055
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
E-EDV-D682, EDV-GC, Gemcitabine, Nab paclitaxel.
Drug
Lead sponsor
Engeneic Pty Limited
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
El Segundo, California • Summit, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 11, 2026, 4:57 PM EDT
Not listed Phase 1 Interventional

Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology

NCT03703089
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Gemcitabine, nab-paclitaxel
Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Phase 3 Interventional

Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

NCT00038402
View directory record Official record
Conditions
Breast Cancer
Interventions
Herceptin, Taxol, Fluorouracil, Cytoxan, Epirubicin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Phase 3 Interventional Results available

Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

NCT00112294
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Paclitaxel (Taxane), Docetaxel (Taxane), Carboplatin, Cetuximab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
124
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 121 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Sep 11, 2026, 4:57 PM EDT
Completed No phase listed Observational

Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel

NCT00003569
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer
Interventions
cisplatin, dimesna, paclitaxel
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
3
States / cities
Chicago, Illinois • Baltimore, Maryland • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

NCT01325441
View directory record Official record
Conditions
Cancer
Interventions
BBI608, Paclitaxel
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
17
States / cities
Los Angeles, California • Denver, Colorado • Indianapolis, Indiana + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Sep 11, 2026, 4:57 PM EDT
Recruiting Phase 3 Interventional

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

NCT06072781
View directory record Official record
Conditions
Low Grade Serous Ovarian Cancer
Interventions
avutometinib, Defactinib, Pegylated liposomal doxorubicin, Paclitaxel, Letrozole, Anastrozole
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
38
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 11, 2026, 4:57 PM EDT
Recruiting Phase 2 Interventional

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

NCT06906341
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
Interventions
Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Palo Alto, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Not applicable Interventional

Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility

NCT00617370
View directory record Official record
Conditions
Breast Cancer, Adenocarcinoma of the Breast
Interventions
epirubicin, cyclophosphamide, Paclitaxel,
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Not applicable Interventional

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer

NCT02064829
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Recurrent Breast Cancer
Interventions
Nab-paclitaxel, IG-001
Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
30 Years and older · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Fayetteville, Arkansas • Chattanooga, Tennessee • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Sep 11, 2026, 4:57 PM EDT
Not listed Phase 1 Interventional

Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer

NCT00004173
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
oxaliplatin, paclitaxel
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Radiation Therapy Followed By Surgery in Treating Patients With Stage IIB or Stage IIIA Non-Small Cell Lung Cancer

NCT00006469
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer

NCT00005051
View directory record Official record
Conditions
Ovarian Cancer
Interventions
carboplatin, cisplatin, paclitaxel, topotecan hydrochloride
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
10
States / cities
Fresh Meadows, New York • New York, New York • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2012 · Synced Sep 11, 2026, 4:57 PM EDT
Recruiting Phase 2 Interventional

Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

NCT05715229
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Nivolumab, Ipilimumab, Carboplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey • Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 11, 2026, 4:57 PM EDT
Not listed Phase 2 Interventional

Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer

NCT00083083
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, docetaxel, etoposide, paclitaxel, vinblastine sulfate, vinorelbine tartrate, gene expression analysis, positron emission tomography, fludeoxyglucose F 18, radiation therapy
Drug · Genetic · Procedure + 1 more
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
46
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Phase 2 Interventional Results available

Treatment With Pazopanib for Neoadjuvant Breast Cancer

NCT00849472
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
doxorubicin + cyclophosphamide, paclitaxel + pazopanib, surgery, pazopanib monotherapy
Drug · Procedure
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
137
States / cities
Decatur, Alabama • Huntsville, Alabama • Antioch, California + 97 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Sep 11, 2026, 4:57 PM EDT
Recruiting Phase 2 Interventional

Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)

NCT07433673
View directory record Official record
Conditions
Colon and Rectal Cancer
Interventions
Cemiplimab
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Phase 1 Interventional Results available

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

NCT03884556
View directory record Official record
Conditions
Solid Tumor, Lymphoma
Interventions
TTX-030, Pembrolizumab, Gemcitabine, nab paclitaxel
Drug
Lead sponsor
Trishula Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Orange, California • Sacramento, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Not applicable Interventional

Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer

NCT04631445
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
Ketogenic Diet
Other
Lead sponsor
Translational Drug Development
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
6
States / cities
Scottsdale, Arizona • Los Angeles, California • Danbury, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 11, 2026, 4:57 PM EDT